menu

On the Horizon: Achieving Durable VEGF Suppression in nAMD and DME

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

On the Horizon: Achieving Durable VEGF Suppression in nAMD and DME

close
0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    One of the biggest challenges with anti-VEGF therapy is the burden of continued and frequent treatment. Fortunately, new options are on the horizon in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) that can safely reduce treatment burden while improving vision. So what are these strategies, and what is the latest evidence for their use?

    Join us as leading experts, Diana Do, Nancy Holekamp, and Carl Regillo, discuss several new strategies to improve VEGF suppression in nAMD and DME. Hear about unique mechanisms of action, the most recent clinical evidence supporting the use of these developments, and their potential applications in clinical practice.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Host:
    Diana Do, MD
    Professor of Ophthalmology
    Stanford University
    Palo Alto, CA

    No relevant relationships to disclose.

    Faculty:
    Nancy M. Holekamp, MD
    Director, Retina Services
    Pepose Vision Institute
    Chesterfield, MO

    Contracted Research: Gemini, Genentech, Notal Vision
    Ownership Interest: Catalyst Pharmaceuticals, Gemini
    Consulting Fees: Adverum, Allergan, Catalyst Pharmaceuticals, Clearside BIO, EyePoint, Gemini, Genentech, Gyroscope, Notal Vision, Novartis, Regeneron
    Advisory Board: Allergan, Genentech, Regeneron, Spark

    Carl Regillo, MD
    Director, Retina Service and Professor of Ophthalmology
    Wills Eye Hospital, Thomas Jefferson University
    Philadelphia, PA

    Contracted Research: Adverum, Aldeyra, Allergan, Annexon, Astellas, Chengdu Kanghong, EyePoint, Genentech, Graybug, Iveric, Kodiak, Lineage, NGM, Notal, Novartis, Opthea, Regeneron, REGENXBIO
    Consulting Fees: Adverum, Aldeyra, Allergan, Annexon, Aviceda, Chengdu Kanghong, EyePoint, Genentech, Graybug, Iveric, Kodiac, Lineage, Merck, NGM, Notal, Novartis, Ocugen, Opthea, Stealth, Takeda, Théa, Zeiss

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Anna Trentini has nothing to disclose.
    • Stephanie Wenick, MPhil, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate available evidence on the efficacy and safety of emerging anti-VEGF strategies designed to reduce treatment burden and improve long-term vision outcomes
    • Identify emerging therapeutic mechanisms to address vascular instability caused by VEGF and Ang-2
    • Examine the benefits and risks of emerging techniques for sustained anti-VEGF delivery in nAMD and DME
  • Target Audience

    This activity is designed to meet the educational needs of ophthalmologists, retina specialists, and other eye health professionals.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by independent educational grants from Genentech, a member of the Roche Group, and F. Hoffmann-La Roche Ltd.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    One of the biggest challenges with anti-VEGF therapy is the burden of continued and frequent treatment. Fortunately, new options are on the horizon in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) that can safely reduce treatment burden while improving vision. So what are these strategies, and what is the latest evidence for their use?

    Join us as leading experts, Diana Do, Nancy Holekamp, and Carl Regillo, discuss several new strategies to improve VEGF suppression in nAMD and DME. Hear about unique mechanisms of action, the most recent clinical evidence supporting the use of these developments, and their potential applications in clinical practice.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Host:
    Diana Do, MD
    Professor of Ophthalmology
    Stanford University
    Palo Alto, CA

    No relevant relationships to disclose.

    Faculty:
    Nancy M. Holekamp, MD
    Director, Retina Services
    Pepose Vision Institute
    Chesterfield, MO

    Contracted Research: Gemini, Genentech, Notal Vision
    Ownership Interest: Catalyst Pharmaceuticals, Gemini
    Consulting Fees: Adverum, Allergan, Catalyst Pharmaceuticals, Clearside BIO, EyePoint, Gemini, Genentech, Gyroscope, Notal Vision, Novartis, Regeneron
    Advisory Board: Allergan, Genentech, Regeneron, Spark

    Carl Regillo, MD
    Director, Retina Service and Professor of Ophthalmology
    Wills Eye Hospital, Thomas Jefferson University
    Philadelphia, PA

    Contracted Research: Adverum, Aldeyra, Allergan, Annexon, Astellas, Chengdu Kanghong, EyePoint, Genentech, Graybug, Iveric, Kodiak, Lineage, NGM, Notal, Novartis, Opthea, Regeneron, REGENXBIO
    Consulting Fees: Adverum, Aldeyra, Allergan, Annexon, Aviceda, Chengdu Kanghong, EyePoint, Genentech, Graybug, Iveric, Kodiac, Lineage, Merck, NGM, Notal, Novartis, Ocugen, Opthea, Stealth, Takeda, Théa, Zeiss

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Anna Trentini has nothing to disclose.
    • Stephanie Wenick, MPhil, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate available evidence on the efficacy and safety of emerging anti-VEGF strategies designed to reduce treatment burden and improve long-term vision outcomes
    • Identify emerging therapeutic mechanisms to address vascular instability caused by VEGF and Ang-2
    • Examine the benefits and risks of emerging techniques for sustained anti-VEGF delivery in nAMD and DME
  • Target Audience

    This activity is designed to meet the educational needs of ophthalmologists, retina specialists, and other eye health professionals.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by independent educational grants from Genentech, a member of the Roche Group, and F. Hoffmann-La Roche Ltd.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule18 Oct 2021